Looking back on immuno-oncology stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Exact ...

Dr. Laurence Albiges presented the poster Characteristics and real-world adherence to ESMO guidelines of patients with advanced Renal Cell Carcinoma (aRCC) in the era of immuno-oncology-based (IO) ...

The FDA has granted approval to pembrolizumab for the treatment of adult patients with resectable, locally advanced HNSCC whose tumors express PD-L1 with a CPS of ≥1. IO Biotech's first-in-class ...

Anant Madabhushi, director of the Center for Computational Imaging and Personalized Diagnostics, had a presentation featured at the Immuno-Oncology 360° conference. His talk, titled “Applying a Novel ...

The following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted ...

The new venture is backed by Biovance Capital, Torrey Pines Investment, and OrbiMed. Mondego Bio is advancing a portfolio of first- and best-in-class PTPN2 inhibitors designed to transform cancer ...